1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted

2. Executive Summary
2.1. Market Snapshot: Global Hospital Acquired Disease Testing Market
2.2. Global Hospital Acquired Disease Testing Market, By Infection Type, 2023 (US$ Million)
2.3. Global Hospital Acquired Disease Testing Market, By Geography, 2023 (US$ Million)
2.4. Attractive Investment Proposition by Geography, 2023

3. Hospital Acquired Disease Testing Market: Competitive Analysis
3.1. Market Positioning of Key Hospital Acquired Disease Testing Market Vendors
3.2. Strategies Adopted by Hospital Acquired Disease Testing Market Vendors
3.3. Key Industry Strategies
4. Hospital Acquired Disease Testing Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Hospital Acquired Disease Testing Market Value, 2022 - 2032, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis
4.6. Porter's Five Force Model
4.6.1. Supplier Power
4.6.2. Buyer Power
4.6.3. Threat Of Substitutes
4.6.4. Threat Of New Entrants
4.6.5. Competitive Rivalry
4.7. PESTEL Analysis
4.7.1. Political Landscape
4.7.2. Economic Landscape
4.7.3. Technology Landscape
4.7.4. Legal Landscape
4.7.5. Social Landscape

5. Hospital Acquired Disease Testing Market: By Infection Type, 2022-2032, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2023 Versus 2032
5.3. Market Segmentation
5.3.1. Pneumonia
5.3.2. Urinary Tract Infection
5.3.3. Blood Stream Infection
5.3.4. Surgical Site Infection
5.3.5. MRSA
5.3.6. Others


6. North America Hospital Acquired Disease Testing Market, 2022-2032, USD (Million)
6.1. Market Overview
6.2. Hospital Acquired Disease Testing Market: By Infection Type, 2022-2032, USD (Million)
6.3.Hospital Acquired Disease Testing Market: By Region, 2022-2032, USD (Million)
6.3.1.North America
6.3.1.1. U.S.
6.3.1.1.1. Hospital Acquired Disease Testing Market: By Infection Type, 2022-2032, USD (Million)
6.3.1.2. Canada
6.3.1.2.1. Hospital Acquired Disease Testing Market: By Infection Type, 2022-2032, USD (Million)
6.3.1.3. Rest of North America
6.3.1.3.1. Hospital Acquired Disease Testing Market: By Infection Type, 2022-2032, USD (Million)

7. UK and European Union Hospital Acquired Disease Testing Market, 2022-2032, USD (Million)
7.1. Market Overview
7.2. Hospital Acquired Disease Testing Market: By Infection Type, 2022-2032, USD (Million)
7.3.Hospital Acquired Disease Testing Market: By Region, 2022-2032, USD (Million)
7.3.1.UK and European Union
7.3.1.1. UK
7.3.1.1.1. Hospital Acquired Disease Testing Market: By Infection Type, 2022-2032, USD (Million)
7.3.1.2. Germany
7.3.1.2.1. Hospital Acquired Disease Testing Market: By Infection Type, 2022-2032, USD (Million)
7.3.1.3. Spain
7.3.1.3.1. Hospital Acquired Disease Testing Market: By Infection Type, 2022-2032, USD (Million)
7.3.1.4. Italy
7.3.1.4.1. Hospital Acquired Disease Testing Market: By Infection Type, 2022-2032, USD (Million)
7.3.1.5. France
7.3.1.5.1. Hospital Acquired Disease Testing Market: By Infection Type, 2022-2032, USD (Million)
7.3.1.6. Rest of Europe
7.3.1.6.1. Hospital Acquired Disease Testing Market: By Infection Type, 2022-2032, USD (Million)

8. Asia Pacific Hospital Acquired Disease Testing Market, 2022-2032, USD (Million)
8.1. Market Overview
8.2. Hospital Acquired Disease Testing Market: By Infection Type, 2022-2032, USD (Million)
8.3.Hospital Acquired Disease Testing Market: By Region, 2022-2032, USD (Million)
8.3.1.Asia Pacific
8.3.1.1. China
8.3.1.1.1. Hospital Acquired Disease Testing Market: By Infection Type, 2022-2032, USD (Million)
8.3.1.2. Japan
8.3.1.2.1. Hospital Acquired Disease Testing Market: By Infection Type, 2022-2032, USD (Million)
8.3.1.3. India
8.3.1.3.1. Hospital Acquired Disease Testing Market: By Infection Type, 2022-2032, USD (Million)
8.3.1.4. Australia
8.3.1.4.1. Hospital Acquired Disease Testing Market: By Infection Type, 2022-2032, USD (Million)
8.3.1.5. South Korea
8.3.1.5.1. Hospital Acquired Disease Testing Market: By Infection Type, 2022-2032, USD (Million)
8.3.1.6. Rest of Asia Pacific
8.3.1.6.1. Hospital Acquired Disease Testing Market: By Infection Type, 2022-2032, USD (Million)

9. Latin America Hospital Acquired Disease Testing Market, 2022-2032, USD (Million)
9.1. Market Overview
9.2. Hospital Acquired Disease Testing Market: By Infection Type, 2022-2032, USD (Million)
9.3.Hospital Acquired Disease Testing Market: By Region, 2022-2032, USD (Million)
9.3.1.Latin America
9.3.1.1. Brazil
9.3.1.1.1. Hospital Acquired Disease Testing Market: By Infection Type, 2022-2032, USD (Million)
9.3.1.2. Mexico
9.3.1.2.1. Hospital Acquired Disease Testing Market: By Infection Type, 2022-2032, USD (Million)
9.3.1.3. Rest of Latin America
9.3.1.3.1. Hospital Acquired Disease Testing Market: By Infection Type, 2022-2032, USD (Million)

10. Middle East and Africa Hospital Acquired Disease Testing Market, 2022-2032, USD (Million)
10.1. Market Overview
10.2. Hospital Acquired Disease Testing Market: By Infection Type, 2022-2032, USD (Million)
10.3.Hospital Acquired Disease Testing Market: By Region, 2022-2032, USD (Million)
10.3.1.Middle East and Africa
10.3.1.1. GCC
10.3.1.1.1. Hospital Acquired Disease Testing Market: By Infection Type, 2022-2032, USD (Million)
10.3.1.2. Africa
10.3.1.2.1. Hospital Acquired Disease Testing Market: By Infection Type, 2022-2032, USD (Million)
10.3.1.3. Rest of Middle East and Africa
10.3.1.3.1. Hospital Acquired Disease Testing Market: By Infection Type, 2022-2032, USD (Million)

11. Company Profile
11.1. Becton Dickinson
11.1.1. Company Overview
11.1.2. Financial Performance
11.1.3. Product Portfolio
11.1.4. Strategic Initiatives
11.2. bioMerieux
11.2.1. Company Overview
11.2.2. Financial Performance
11.2.3. Product Portfolio
11.2.4. Strategic Initiatives
11.3. Cantel
11.3.1. Company Overview
11.3.2. Financial Performance
11.3.3. Product Portfolio
11.3.4. Strategic Initiatives
11.4. Cepheid
11.4.1. Company Overview
11.4.2. Financial Performance
11.4.3. Product Portfolio
11.4.4. Strategic Initiatives
11.5. Diatherix
11.5.1. Company Overview
11.5.2. Financial Performance
11.5.3. Product Portfolio
11.5.4. Strategic Initiatives
11.6. Qiagen
11.6.1. Company Overview
11.6.2. Financial Performance
11.6.3. Product Portfolio
11.6.4. Strategic Initiatives
11.7. Nordion
11.7.1. Company Overview
11.7.2. Financial Performance
11.7.3. Product Portfolio
11.7.4. Strategic Initiatives
11.8. Roche
11.8.1. Company Overview
11.8.2. Financial Performance
11.8.3. Product Portfolio
11.8.4. Strategic Initiatives
11.9. Others
11.9.1. Company Overview
11.9.2. Financial Performance
11.9.3. Product Portfolio
11.9.4. Strategic Initiatives